StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
Zacks.com on MSN6d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on November 25 and set a price target of ...
Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback